Prostate cancer diagnosis may lead to CV events

Sandler, Howard
June 2008
Cardiology Today;Jun2008, Vol. 11 Issue 6, p34
The article reports that the researchers from Karolinska Institutet, Sweden revealed that patients are at increased risk for fatal and nonfatal cardiovascular events after being diagnosed with prostate cancer. From 168,584 prostate cancer cases from the Swedish Cancer Register identified by the researchers, 7,429 incidents of fatal cardiovascular events were found within the first year after diagnosis and 3,655 incidents of non-fatal cardiovascular events.


Related Articles

  • Sweet's syndrome in prostate cancer. Glendenning, J.; Khoo, V. // Prostate Cancer & Prostatic Diseases;2008, Vol. 11 Issue 4, p397 

    Originally described in 1964 as an idiopathic dermatosis occurring in women, Sweet's syndrome (acute febrile neutrophilic dermatosis) is associated with malignancy, typically haematological. We report a case occurring in a man receiving radical radiotherapy for locally advanced prostate cancer....

  • Lessons From the CaPSURE Database. Cooperberg, Matthew R. // AUANews;Oct2008, Vol. 13 Issue 10, p9 

    This article explores lessons learned from the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) registry. CaPSURE is an observational database of patients with prostate cancer treated at a variety of clinical practice settings throughout the U.S. A study by CaPSURE in 2008...

  • Androgen Deprivation Therapy and Cardiovascular Risk in Chinese Patients with Nonmetastatic Carcinoma of Prostate. Gang Huang; Chun-Yip Yeung; Ka Kui Lee; Jianxiong Liu; Kwan Lun Ho; Ming-Kwong Yiu; Karen Siu-Ling Lam; Hung-Fat Tse; Yau, Thomas; Chung-Wah Siu // Journal of Oncology;2014, p1 

    Background. Androgen deprivation therapy (ADT) in nonmetastatic prostate cancer is unclear. Recent data suggests possible increase in the cardiovascular risks receiving ADT. The aim of the study was to investigate the cardiovascular outcomes in a cohort of Chinese nonmetastatic prostate cancer...

  • Robotic Radical Prostatectomy in Patients with Previous Prostate Surgery and Radiotherapy. Acar, ├Âmer; Esen, Tarik // Prostate Cancer (20903111);2014, p1 

    Herein, we will review the available literature about robot-assisted radical prostatectomy in patients who have undergone prostate surgery or radiotherapy. Current data about this topic consists of small case series with limited follow-up. Despite being technically demanding, robot-assisted...

  • A Guide to Prostate Cancer's Sexual Side Effects. Bicklein, Sherry // Radiation Therapist;Fall2009, Vol. 18 Issue 2, p172 

    The article reviews the book "Sexual Function in the Prostate Cancer Patient," by J. P. Mulhall.

  • Bone complications among prostate cancer survivors: long-term follow-up from the prostate cancer outcomes study. Morgans, A K; Fan, K-H; Koyama, T; Albertsen, P C; Goodman, M; Hamilton, A S; Hoffman, R M; Stanford, J L; Stroup, A M; Penson, D F // Prostate Cancer & Prostatic Diseases;Dec2014, Vol. 17 Issue 4, p338 

    Background:To assess the relationship between androgen deprivation therapy (ADT) exposure and self-reported bone complications among men in a population-based cohort of prostate cancer survivors followed for 15 years after diagnosis.Methods:The Prostate Cancer Outcomes Study enrolled 3533...

  • Risk of CV disorders and diabetes with GnRH agonist use.  // Reactions Weekly;10/14/2006, Issue 1123, p5 

    The article discusses research being done on the risk of cardiovascular disorders and diabetes with gonadotropin releasing hormone (GnRH) use. Compared with androgen deprivation therapy, the use of GnRH agonists appears to be associated with an increased risk of incident diabetes mellitus and...

  • ADT associated with increased risk for diabetes, CHD. Haigh, Christen; Lawrence, Leah // Hem/Onc Today;1/10/2010, Vol. 11 Issue 1, p24 

    The article deals with a study that examined the risk for diabetes and cardiovascular disease in prostate cancer patients treated with gonadotropin-releasing hormone agonists or androgen deprivation therapy.

  • Treament-related diabetes and cardiovascular disease in prostate cancer survivors. Smith, M. R. // Annals of Oncology;Sep2008 Supplement 7, Vol. 19, p86 

    The article examines whether gonadotropin-releasing hormone (GnRH) agonists increase the risk for diabetes and cardiovascular disease in prostate cancer survivor. It states that although GnRH agonists improve survival in various settings, they have adverse effects such as vasomotor flushing,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics